Loading organizations...
§ Private Profile · New York City, NY, USA
An AI and data analytics company using computer vision to monitor medication adherence and patient behavior for clinical trials and patient engagement.
Based in New York, New York, AiCure is an artificial intelligence and advanced data analytics company that utilizes computer vision and machine learning to monitor medication adherence and patient behavior during clinical trials. The business operates a software licensing model, deploying its remote patient engagement and digital biomarker platform across more than 30 countries. The enterprise maintains a portfolio of over 84 issued patents and operates with an estimated workforce of 100 to 200 employees. AiCure has secured over $50 million in total venture funding, including a $24.5 million Series C round, supported by institutional investors such as Baird Capital, New Leaf Venture Partners, and Biomatics Capital. The platform also receives grant funding from the National Institutes of Health to accelerate drug development for pharmaceutical companies. AiCure was founded in 2010 by Adam Hanina and Laura Bessen.
AiCure has raised $52.0M across 3 funding rounds.
AiCure has raised $52.0M in total across 3 funding rounds.
AiCure has raised $52.0M in total across 3 funding rounds.
AiCure's investors include Jeff Anderson, Nasdaq Ventures, Marco DeMeireles, TIDE Africa Fund, Tribeca Venture Partners, Stanton Green, Accelmed, Asahi Kasei, Baird Capital, Biomatics Capital, New Leaf Venture Partners, Pritzker Group.
AiCure has raised $52.0M across 3 funding rounds. Most recently, it raised $25.0M Series C in November 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2019 | $25M Series C | Jeff Anderson | Nasdaq Ventures, Marco Demeireles, Tide Africa Fund, Tribeca Venture Partners, Stanton Green, Accelmed, Asahi Kasei, Baird Capital, Biomatics Capital, NEW Leaf Venture Partners, Pritzker Group, Silicon Valley Bank, Singtel Innov8, Springrock Ventures | Announced |
| Nov 1, 2017 | $15M Series B | — | Nasdaq Ventures, Marco Demeireles, Tide Africa Fund, Tribeca Venture Partners, Stanton Green | Announced |
| Jan 1, 2016 | $12M Series A | Vijay Lathi | Nasdaq Ventures, Marco Demeireles, Tide Africa Fund, Tribeca Venture Partners, Stanton Green, Boris Nikolic, Pritzker Group Venture Capital | Announced |
AiCure is a patient-centric eClinical trials management platform that leverages AI, computer vision, and machine learning to empower life science organizations, pharmaceutical companies, CROs, and healthcare providers.[1][2][3] It builds H.Code, a comprehensive patient engagement AI platform that enables remote monitoring of patient behavior, real-time dosing support, digital biomarker measurement, and predictive insights to improve adherence, data quality, and trial outcomes across all therapeutic areas.[4][5] Serving clients like AbbVie and Abbott in over 46 countries, AiCure solves key clinical trial challenges—such as poor patient adherence, incomplete data, high costs, and delayed drug development—by providing unbiased, objective insights from smartphone-captured audio, visual, and behavioral data, reducing early termination rates to as low as 7.8% in studies with over 4,000 patients.[2][3][5] The company demonstrates strong growth momentum through $12M+ in Series A funding, 84+ patents, and awards like Scrip Award and AI 100.[2]
AiCure was founded in 2010 in New York, NY, by a team blending healthcare, engineering, and behavioral science expertise: Adam Hanina (vision for computer vision in healthcare and current CEO role), Gordon Kessler (partnerships and legal), Laura Schafner (behavior prediction inspired by her psychiatrist father's bipolar disorder struggles and the need for a "360 view of the patient"), and Lei Guan (principal engineer).[1][2] The idea emerged from applying finance-like predictive models to public health, scaling nurse-patient interactions via technology to assess risk and adherence.[1] Early traction came via a $273K NIH SBIR grant, pioneering unbiased AI like diverse facial recognition, leading to AiCure's first AbbVie contract, a patent issuance, $12M Series A funding, and the 2016 Alconics Award.[1][2]
AiCure stands out in clinical trials through these key strengths:
AiCure rides the decentralized clinical trials wave, fueled by post-pandemic demand for remote, patient-friendly solutions amid rising trial costs (often exceeding $1B per drug) and adherence issues dropping 20-30% of participants.[2][5] Timing aligns with AI maturation in healthcare—computer vision and predictive analytics now enable scalable, real-world evidence from diverse populations, addressing regulatory pushes for inclusivity (e.g., FDA diversity guidelines).[1][4] Market forces like pharma's $100B+ annual R&D spend and CRO growth favor AiCure, as its platform accelerates timelines, cuts costs via virtual monitoring, and boosts data integrity for faster approvals.[2][3] It influences the ecosystem by setting standards for responsible AI, enhancing trial statistical power, and bridging patients/sites/sponsors, with research validating adherence as a retention predictor.[5]
AiCure is poised to expand H.Code into broader personalized care beyond trials, integrating with wearables, EHRs, and companion apps for real-world evidence generation.[1][4] Trends like multimodal AI, regulatory emphasis on digital endpoints, and global trial decentralization will propel growth, potentially capturing share in the $50B+ eClinical market. Its influence may evolve toward leading AI ethics in health tech, powering proactive interventions that cut dropouts further and inform commercialization—reinforcing its founding vision of predictive, unbiased patient insights at scale.[1][2][5]